Skip to Main Content

Paper Details

Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
J Clin Oncol
37
2022
Author NameAffiliation
Gautam BorthakurThe University of Texas MD Anderson Cancer Center
Courtney D DiNardoThe University of Texas MD Anderson Cancer Center
Rashmi Kanagal-ShamannaThe University of Texas MD Anderson Cancer Center
Guillermo Garcia-ManeroThe University of Texas MD Anderson Cancer Center
Farhad RavandiThe University of Texas MD Anderson Cancer Center
Hagop KantarjianThe University of Texas MD Anderson Cancer Center
  • 1 - 6

Datasets

Release 1.2